(Source: Enanta Pharmaceuticals Inc) 97-98 percent SVRachieved with eight weeks of ABT-493 and ABT-530 treatment ingenotypes 1, 2 or 3 HCV patients without cirrhosis in SURVEYOR 1 and 2 studies 100 percent SVRachieved with 12 weeks of treatment in difficult-to-treat genotype 3 patients with compensated cirrhosis (Child-Pugh A)new to therapy 100 percent SVR achieved with 12 weeks of treatment in genotypes 4, 5 or 6 patients without cirrhosiss; eight-week treatment duration being investigated in this ongoing study ABT-493 is Enanta's second protease inhibitor being developed in combination with ABT-530, AbbVie's NS5A inhibitor WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 16, 2016-- Enanta...
↧